No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Founded in 1994 and headquartered in Toyonaka, Japan, Soiken Holdings Inc. primarily focuses on the advancement of biomarkers. The company’s operations span a diverse range of health and wellness sectors. It is actively involved in the creation and commercialization of cosmetics and nutritional supplements, alongside the licensing and continued development of biomarker technologies. Soiken also conducts market research and post-market surveillance specifically for dietary supplements. A key area of its work includes the research, development, and sale of functional materials like lactoferrin, as well as pharmaceuticals derived from ascochlorin. Furthermore, Soiken applies its biomarker expertise to perform clinical evaluations for food products. The company extends its services to provide vital support for physician-initiated pharmaceutical clinical research, comprehensive health screenings, and personalized health guidance. It also partners with health insurance societies to offer contracted health guidance, facilitate specialized health check-ups for dependents of the insured, and implement programs designed for diabetes prevention.

• Enlivex Therapeutics Ltd.
• Nicox S.A.
• NaviFUS Corp.
• GeneReach Biotechnology Corp.
• Lantern Pharma Inc.
• Mendus AB (publ)
• Public Joint-Stock Company "Human Stem Cells Institute"
• LabTurbo Biotech Corporation